Home  |  Contact

UniProtKB/Swiss-Prot O60931: Variant p.Gly339Arg

Cystinosin
Gene: CTNS
Chromosomal location: 17p13
Variant information

Variant position:  339
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Arginine (R) at position 339 (G339R, p.Gly339Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Cystinosis, nephropathic type (CTNS) [MIM:219800]: A form of cystinosis, a lysosomal storage disease due to defective transport of cystine across the lysosomal membrane. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. The classical nephropathic form has onset in the first year of life and is characterized by a polyuro-polydipsic syndrome, marked height-weight growth delay, generalized impaired proximal tubular reabsorptive capacity, with severe fluid-electrolyte balance alterations, renal failure, ocular symptoms and other systemic complications. {ECO:0000269|PubMed:10482956, ECO:0000269|PubMed:10556299, ECO:0000269|PubMed:12204010, ECO:0000269|PubMed:12442267, ECO:0000269|PubMed:12825071, ECO:0000269|PubMed:19852576, ECO:0000269|PubMed:21786142, ECO:0000269|PubMed:22450360, ECO:0000269|PubMed:9792862}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In CTNS.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  339
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  367
The length of the canonical sequence.

Location on the sequence:   QSYNNDQWTLIFGDPTKFGL  G VFSIVFDVVFFIQHFCLYRK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QSYNNDQWTLIFGDPTKFGLGVFSIVFDVVFFIQHFCLYR--K

Mouse                         QSYNNDQWTLIFGDPTKFGLGVFTIFFDVVFFIQHFYLYR-

Bovine                        QSYNNDQWTLIFGDPTKFGLGIFSIIFDVVFFIQHFCLYR-

Caenorhabditis elegans        QAVNVNDWSAFYANPVKFGLGFVSIFFDIIFMVQHYVLYPN

Drosophila                    NAHNYDDWVSIFGDPTKFGLGLFSVLFDVFFMLQHYVFYRH

Slime mold                    DVADSGNWNIFTGDPVKLGLSLFSIAFDILFIIQHYILYRN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 367 Cystinosin
Transmembrane 336 – 356 Helical


Literature citations

CTNS mutations in an American-based population of cystinosis patients.
Shotelersuk V.; Larson D.; Anikster Y.; McDowell G.; Lemons R.; Bernardini I.; Guo J.; Thoene J.; Gahl W.A.;
Am. J. Hum. Genet. 63:1352-1362(1998)
Cited for: VARIANTS CTNS ASP-169; ARG-182; ASN-205; ASP-205 DEL; ASN-298; GLY-305; ARG-308 AND ARG-339; VARIANT CTNSJAN 67-ILE--PRO-73 DEL; VARIANT ARG-292;

Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin.
Attard M.; Jean G.; Forestier L.; Cherqui S.; van 't Hoff W.; Broyer M.; Antignac C.; Town M.;
Hum. Mol. Genet. 8:2507-2514(1999)
Cited for: VARIANTS CTNS PHE-139; SER-270 DEL; TYR-305; ARG-308; PRO-338; ARG-339 AND ASN-346; VARIANT ILE-42;

Analysis of the CTNS gene in patients of German and Swiss origin with nephropathic cystinosis.
Kiehntopf M.; Schickel J.; Gonne B.; Koch H.G.; Superti-Furga A.; Steinmann B.; Deufel T.; Harms E.;
Hum. Mutat. 20:237-237(2002)
Cited for: VARIANTS CTNS VAL-308 AND ARG-339;

Mutational spectrum of the CTNS gene in Italy.
Mason S.; Pepe G.; Dall'Amico R.; Tartaglia S.; Casciani S.; Greco M.; Bencivenga P.; Murer L.; Rizzoni G.; Tenconi R.; Clementi M.;
Eur. J. Hum. Genet. 11:503-508(2003)
Cited for: VARIANTS CTNS ILE-287; ARG-308; ARG-337 AND ARG-339; VARIANT ILE-260;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.